What the research found
Researchers using human patient samples, mouse models, and cell cultures found that impaired clearance of damaged mitochondria—a process called mitophagy—is a driver of neurodegeneration. As we age, mitochondrial quality-control pathways become suppressed, allowing dysfunctional mitochondria to accumulate. This triggers oxidative stress and breaks down synaptic connections between neurons. When the team reactivated mitophagy through both genetic and pharmacological means, they restored mitochondrial health, improved how neurons used energy, and slowed neurodegeneration—even when treatment started after disease had already begun.
A separate analysis in Science reexamined how much of human lifespan variation is genetic. Previous estimates suggested genetics accounted for only 15–25% of lifespan differences. The new work used mathematical survival models and large twin and population datasets to separate deaths from intrinsic ageing (disease and cellular decline) from extrinsic causes (accidents, infections, violence). Once this noise was filtered out, genetic factors explained roughly 40–50% of variation in how long people live from ageing-related causes alone—placing longevity on par with other heritable traits like height.
Why it matters for you
If mitophagy activation proves translatable to humans, it could offer a novel angle on protecting cognitive function and potentially slowing conditions like Alzheimer's or Parkinson's. Currently, MyKine users tracking neurological biomarkers (if available via advanced blood work) or subjective cognitive performance have limited intervention levers beyond exercise, sleep, and general antioxidant support. A mitophagy-targeting therapy—whether small molecule, peptide, or other modality—would represent a more direct mechanistic approach to clearing senescent mitochondria in neurons, the cell type most sensitive to energy failure.
The lifespan heritability finding is more foundational: it tells you that your genetic background substantially influences your ageing rate and maximum healthspan potential. This doesn't mean genetics is destiny, but it does reframe longevity as a trait shaped primarily by biology rather than accident. For protocol design, it underscores why tracking and optimising biomarkers tied to intrinsic ageing—VO₂ max, inflammatory markers, glucose control, mitochondrial function where measurable—may have outsized returns compared to efforts to mitigate purely environmental risks.
Caveats
- Mitophagy work combines animal models (mice) and cell culture with human samples; efficacy and safety in living patients unknown
- No human clinical trial data yet; pharmacological and genetic interventions tested in disease models, not healthy ageing
- Lifespan heritability estimate relies on mathematical modelling and assumptions about how to separate intrinsic from extrinsic mortality—real-world validity depends on data quality and model correctness
- The 40–50% figure applies specifically to ageing-related mortality; actual clinical healthspan may be influenced by factors outside this narrow definition